Why did XTLB's EPS remain stagnant in recent quarters?

XTL Biopharmaceuticals Ltd. (XTLB) has not reported a stable EPS in recent quarters due to several factors: 1. **Revenue Decline**: The company's total revenue has not been growing, with the most recent figure reported at $162,000. This decline in revenue could be a contributing factor to the stagnant EPS. 2. **Net Income Loss**: XTLB has reported a net loss of $553,000 for the MRQ, which is a significant negative impact on the company's financial performance. The net income growth rate is -157.21%, indicating a substantial deterioration in profitability. This loss contributes to the lack of EPS growth. |code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code| |---|---|---|---|---|---|---|---| |XTLB|XTLB.O|Xtl Biopharmaceuticals|2023 Q4|62.03208556149733|||186| |XTLB|XTLB.O|Xtl Biopharmaceuticals|2024 Q1|152.77475516866159|||186| |XTLB|XTLB.O|Xtl Biopharmaceuticals|2024 Q2|-93.4065934065934|||186| |XTLB|XTLB.O|Xtl Biopharmaceuticals|2024 Q3|-157.2093023255814|||186| 3. **High Net Margin**: The company's net margin is extremely low, at -476.54%. This indicates that the company's expenses are far greater than its revenues, leading to a negative EPS. In conclusion, XTLB's EPS remains stagnant due to a combination of declining revenue, significant net losses, and extremely negative net margins.